Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Patients must be non-smokers
Patients must have at least one measurable lesion
Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale
Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.
You may not be if
Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication
Patients who have previously received treatment with drugs against the human epidermal growth factor receptors
Patients who have previously received treatment with drugs which have similar targets as Pemetrexed
Patients who have any known significant ophthalmologic abnormalities of the surface of the eye
Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed
Clareo Health | A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
